Stopping sepsis by targeting sphingosine kinase 1

Each year, more than a half million people in the United States alone die from sepsis, a dire multisystem disease with highly inadequate treatment options. In a recent issue of Science, Puneet and colleagues provide compelling evidence that inhibiting sphingosine kinase 1--an enzyme that resides in...

Full description

Saved in:
Bibliographic Details
Published inScience translational medicine Vol. 2; no. 36; p. 36ps29
Main Author O'Neill, Luke A J
Format Journal Article
LanguageEnglish
Published United States 16.06.2010
Subjects
Enzyme Inhibitors - pharmacology
Enzyme Inhibitors - therapeutic use
Humans
Phosphotransferases (Alcohol Group Acceptor) - antagonists & inhibitors
Phosphotransferases (Alcohol Group Acceptor) - metabolism
Sepsis - drug therapy
Sepsis - enzymology
Signal Transduction - drug effects
Online AccessGet more information

Cover

More Information
Summary:Each year, more than a half million people in the United States alone die from sepsis, a dire multisystem disease with highly inadequate treatment options. In a recent issue of Science, Puneet and colleagues provide compelling evidence that inhibiting sphingosine kinase 1--an enzyme that resides in immune cells and is activated by inflammatory signals--might have great potential as a therapy for septic shock.
ISSN:1946-6242
DOI:10.1126/scitranslmed.3001299